– USA, MA – VBI Vaccines Inc. (Nasdaq: VBIV), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the appointment of Linda Bain, CFO of Codiak BioSciences, Inc., to its Board of Directors.
“Linda has extensive experience driving the business and financial strategy of biotech companies and we are delighted to be able to welcome her to our Board,” said CEO, Jeff Baxter. “Linda’s proven track record of translating scientific achievements into organizational and financial growth, and her deep knowledge of the life sciences industry and financial management will make her an instrumental director as VBI prepares for the corporate milestones and evolution ahead.”
About Linda Bain
Ms. Bain is an accomplished financial and business executive with more than two decades of finance, strategy, and board experience in both small and large public companies in the biotechnology and pharmaceutical industry.
As CFO of Codiak BioSciences, Inc., Ms. Bain led the company through its initial public offering and first follow-on financing, building on the success of earlier-stage financing rounds. Ms. Bain plays a lead role in establishing Codiak’s strategic direction and she built and leads finance and business operations, including investor relations and corporate communications, finance, accounting, facilities, and information technology. Before joining Codiak, Ms. Bain was CFO at Adverum Biotechnologies, Inc. (previously Avalanche Biotechnologies, Inc.) and Vice President, Finance, Business Operations, and Treasurer at bluebird bio, Inc., where she played an instrumental role in the IPO for each company. Ms. Bain has also held leadership roles at Genzyme Corporation, including Vice President, Finance, Global Manufacturing and Operations, and Vice President, Finance of Genzyme Genetics, in addition to senior roles at Fidelity Investments, AstraZeneca Pharmaceuticals, and as an auditor at Deloitte & Touche.
“I am excited to be joining VBI’s Board at such a transformational time,” said Linda Bain. “VBI has an impressive pipeline and management team, and I look forward to working with my fellow directors to help guide VBI’s strategy as the team works to advance multiple meaningful clinical candidates and to prepare for the launch of the company’s 3-antigen hepatitis B vaccine candidate.”
Ms. Bain also serves on the Board of Directors for Autolus Therapeutics plc and Arvinas, Inc. She received a Bachelor of Science in Accounting and Business Administration and an Honors degree in Accounting and Business Administration from the University of the Free State, located in South Africa.
About VBI Vaccines Inc.
VBI Vaccines Inc. is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles, including a proprietary enveloped VLP platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus, as well as aggressive cancers including glioblastoma. VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.
For more information: https://www.vbivaccines.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.